Clinical Trials Search Results

This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant).

This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant).

This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant).

2-cohort, Double-blind, Placebo-controlled, Study with Physician’s Choice New Hormonal Agents in Patients with Prostate Cancer

This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.

Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy

Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer